Concepedia

Robin Merkx

RM

Statistics

Publications

5

Citations

268

H-Index

5

Active since

2021

Affiliations

Radboud University Nijmegen(Current)

Radboud University Medical Center

University of California, Los Angeles

Ghent University Hospital

ABX-CRO Advanced Pharmaceutical Services (Germany)

Robin Merkx is an author at Radboud University Nijmegen specializing in renal cell carcinoma, oncology, and renal nuclear imaging.

ORCID

Publications per year

2021–2024

5

Publications

5

[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial

Brian Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard et al. · The Lancet Oncology · 2024 · 127 citations · Full text

, , +13

Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma

Robin Merkx, Daphne Lobeek, Mark Konijnenberg et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 69 citations · Full text

, , +15

Results from phase 3 study of <sup>89</sup>Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).

Brian Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard et al. · Journal of Clinical Oncology · 2023 · 37 citations

, , +17

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model

Robin Merkx, Mark Rijpkema, Gerben M. Franssen et al. · Pharmaceuticals · 2022 · 25 citations · Full text

, , +17

<sup>89</sup>Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study.

Brian Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard et al. · Journal of Clinical Oncology · 2023 · 10 citations

, , +17

1–5 of 5